RxDoctor Payments DataLook up a doctor →

Titus Abraham, MD

Internal Medicine · Annapolis, MDNPI 1598764540

Payments from drug & device makers

$1,722,582in general payments, 2019–2025

Across 384 payments — averaging $4485.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$598K
  • Exact Sciences$324K
  • AstraZeneca$318K
  • Genentech, Inc.$246K
  • Merck$151K
  • Amgen$59K
  • plus $26K from 39 others

What the payments were for

  • Travel & lodging$88814%
  • Food & beverage$5,26086%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,722,582 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$360,711
Medicare patients
899
Services billed
5,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$103,162
JardianceEmpagliflozin42$67,482
OzempicSemaglutide39$50,979
XareltoRivaroxaban45$36,678
RybelsusSemaglutide12$30,855
MounjaroTirzepatide28$30,482
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$22,923
FarxigaDapagliflozin Propanediol13$17,105
TrulicityDulaglutide16$15,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$14,489
Rosuvastatin Calcium398$11,594
Atorvastatin Calcium725$11,211
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$11,066
Pravastatin Sodium215$4,511
Levothyroxine Sodium344$4,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$675$103,16283 claims
Novo NordiskOzempic, Rybelsus$574$81,83451 claims
Boehringer IngelheimJardiance$110$67,48242 claims
Lilly USA, LLCMounjaro, Trulicity$245$45,61644 claims
GSKAnoro Ellipta, Trelegy Ellipta$247$37,41228 claims
Johnson & JohnsonXarelto$64$36,67845 claims
AstraZenecaFarxiga$318,459$17,10513 claims
AbbVieSynthroid$791$2,23039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →